Helsinn's Akynzeo received FDA approval for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adult patients [1]. The approval was based on clinical trials demonstrating its efficacy [1].
How effective is Akynzeo for CINV?
Akynzeo is a fixed combination of netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-3 (5-HT3) receptor antagonist [1]. This dual mechanism targets both acute and delayed phases of CINV [2]. Clinical studies have shown Akynzeo to be effective in achieving a complete response, defined as no emesis and no use of rescue medication, in both the acute (0-24 hours) and delayed (24-120 hours) post-chemotherapy periods [1][2].
When was Akynzeo first approved?
Akynzeo received its initial approval from the U.S. Food and Drug Administration (FDA) in October 2015 [1].
What are the active ingredients in Akynzeo?
Akynzeo contains two active pharmaceutical ingredients: netupitant and palonosetron [1]. Netupitant works by blocking the NK1 receptor, while palonosetron blocks the 5-HT3 receptor [2].
Are there any reported side effects of Akynzeo?
Common side effects associated with Akynzeo include fatigue, headache, and constipation [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
What chemotherapy regimens is Akynzeo used with?
Akynzeo is indicated for use with initial doses of moderately or highly emetogenic cancer chemotherapy [1]. This includes both platinum-based and anthracycline and cyclophosphamide-based regimens [1].
What is the difference between Akynzeo and other anti-nausea medications?
Akynzeo's formulation combines two classes of antiemetics, NK1 receptor antagonists and 5-HT3 receptor antagonists, in a single oral capsule [1][2]. This combination offers a dual mechanism of action that addresses both acute and delayed nausea and vomiting [2]. Other anti-nausea treatments may involve single-agent therapies or different combinations of drugs.
Where can I find more information on drug approvals and patents?
DrugPatentWatch.com provides comprehensive information on drug approvals, patent expirations, and the pharmaceutical landscape [3].